After Fine, Botox Awaits Approval for Migraine

Allergan will pay $600 million for its marketing tactics while the F.D.A. decides on the drug's use for migraines.

14°C - Sunny Spells with only patchy cloud

MIGRAINE sufferers often pop a pill to relieve pain but an alternative treatment is on offer.

License Agreement for Breakthrough Pain Relief Product Drives Launch of Renewal Technologies

PHOENIX -- Bob Gottschalk believes that lightning can strike twice. In fact, with the launch of his new business venture -- Renewal Technologies -- he's betting on it.

Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies

Reportlinker.com announces that a new market research report is available in its catalogue:

Research and Markets: Pipeline and Commercial Insight: Migraine - Challenges Ahead for First-in-Class Developments

DUBLIN----Research and Markets has announced the addition of the "Pipeline and Commercial Insight: Migraine - Challenges Ahead for First-in-Class Developments" report to their offering.

Why Allergan's Paying $600 Million Fine for a Botox Marketing Campaign - BlissTree (blog)

New York Times

Why Allergan's Paying $600 Million Fine for a Botox Marketing Campaign BlissTree (blog) The good news is that Botox is awaiting real FDA approval for migraine use (and you can still ask your doctor about it in the meantime). ... After Fine, Botox Awaits Approval for MigraineSarasota Herald-Tribune all 22 news articles »